Natco Pharma Shares Jump Over 10% on Semaglutide Approval

Natco Pharma shares surged more than 10 percent after securing regulatory approval to launch the diabetes drug Semaglutide in India. The approval significantly strengthens its foothold in the rapidly expanding anti-diabetes market. Investors reacted positively, anticipating meaningful revenue growth and improved market share. Analysts believe successful commercialization and strong demand could enhance earnings visibility and reinforce Natco Pharma’s competitive positioning within the domestic pharmaceutical sector.